Suzhou Ribo Life

Company snapshot

Established in 2007, Suzhou Ribo Life Science Co., Ltd. (Ribo) is a clinical stage company devoted to the development of innovative RNAi technologies and oligonucleotide therapeutics as an effort to address unmet clinical needs in the world with the tools, capacity and RNA therapeutics that we build up in China. Fueled by our mission to make China's oligonucleotide therapeutics serve the world, we

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Suzhou Ribo Life. Not investment advice.

• What is Suzhou Ribo Life?

  Suzhou Ribo Life is a pharma organization headquartered in CN. Primary therapeutic focus areas include Obese, Hyperlipemia, Non-small Cell Lung Cancer, Rheumatoid Arthritis (RA). NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity

• Is Suzhou Ribo Life publicly traded?

  Suzhou Ribo Life appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Suzhou Ribo Life develop or market?

  We link 7 drug profile(s) where Suzhou Ribo Life is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/suzhou-ribo-life-science-co#company-drugs.

• What are the latest developments for Suzhou Ribo Life?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Suzhou Ribo Life focus on?

  Suzhou Ribo Life focuses on Obese, Hyperlipemia, Non-small Cell Lung Cancer based on our analysis of their pipeline programs and drug development activities.